Business
MED3000 FM71 Presentation at ESSM Congress 2023
MED3000 FM71 Presentation at ESSM Congress 2023.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n 15 February 2023\n \n \n \n \n Futura Medical plc\n \n \n \n \n (\"Futura\" or the \"Company\")\n \n \n \n \n Futura Medical to present MED3000 FM71 data at the European Society for Sexual Medicine Congress 2023\n \n \n \n \n \n \n Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology, with a current focus on sexual health and pain, today announces that it will be presenting data on its lead product MED3000 for the treatment of erectile dysfunction (\"ED\") at the European Society for Sexual Medicine (ESSM) Congress in Rotterdam, The Netherlands on the 16-18 February 2023.\n \n \n \n \n \n MED3000 is a breakthrough, fast acting topical gel formulation with a unique evaporative mode of action, which is applied to the glans penis by the male or his partner for the treatment of ED. MED3000, is CE marked in Europe and CA marked in the UK, as a clinically proven topical treatment for adult men with ED that helps men get an erection within 10 minutes.\n \n \n \n Ken James, Executive Director and Head of R&D at Futura Medical said:\n \n \"We are pleased to present the previously reported, highly positive MED3000 data at ESSM. Erectile dysfunction has a significant impact on the quality of life, relationships and overall wellbeing of sufferers and their partners. MED3000 has the required efficacy, speed of onset and favourable safety profile consistent with an over-the-counter, use therapy. It will help address the needs of many men who for whatever reason are not treating their condition or are dissatisfied with their current treatment. We are excited at the prospect of bringing a truly unique and differentiated treatment option to the market.\"\n \n \n \n \n \n The Poster will be presenting the\n \n recent, positive FM71 Phase 3 Study Results\n \n .\n \n \n \n Details of the presentation are as follows:\n \n \n \n \n \n \n \n Poster Presentation\n \n \n \n \n Abstract:\n \n MED3000, a clinically proven, fast-acting topical product for Erectile Dysfunction with the prospect of being the first globally available OTC treatment for ED\n \n \n \n Authors\n \n :\n David Ralph1, Tim Holland2, Ken James2\n \n \n \n Date & Time:\n \n 16 February, 10.00 CET\n \n \n \n Booth:\n...